Table 1 Comparison of clinical characteristics of patients with and without advanced fibrosis (as determined by ELF score of ≥ 10.5)

Age mean sd

53.11 ± 14.37

55.7 ± 12.6

52.1 ± 15

0.266

Male sex n (%)

68/99 (69)

19/28 (68)

49/71 (69)

0.911

BMI mean sd

26.52 ± 5.94

26.4 ± 5.7

26.6 ± 6.1

0.903

T2DM diagnosis (%)

10/99 (10.1%)

4/28 (14.3%)

6/71 (8.5%)

0.46

Smoking status n (%)

 Non-smoker

15 (16)

6 (21)

9 (13)

0.35

 Smoker

69 (73.4)

16 (57)

53 (75)

0.1

 Ex-smoker

10 (10.6)

5 (18)

5 (7)

0.14

 Unknown

5 (5)

1 (4)

4 (6)

Ongoing active drinking n (%)^a

96/99 (97)

26/28 (93)

70/71 (99)

0.19

Current alcohol intake U/w, median (IQR)

140 (80.9–280)

112 (70–210)

150 (105–280)

0.031

Years of harmful drinking median (IQR)

15 (10–27.5)

20 (10–28)

15 (7.5–28)

0.357

Signs of CLD on exam

 Yes n (%)

4 (4%)

4 (14.3)

0 (0%)

0.005

 No n (%)

95 (96%)

24 (85.7)

71 (100%)

Abnormal LFTs at referral^b

 Yes

63 (66.3%)

18 (64.3)

45 (63.4%)

0.712

 No

32 (33.7%)

8 (28.6)

24 (33.8%)

 N = 

95

26

69

ALT IU/L median (IQR)

39 (21–73)

38 (14–76)

41 (22–71.75)

0.792

AST IU/L median (IQR)

43 (24–86.5)

52 (21–149)

40 (25.5–79.5)

0.493

MCV IU/L median (IQR)

96.9 (91.2–100.5)

97.8 (91.8–101.7)

96.8 (91.2–99.8)

0.522

Platelet count × 10⁹/L median (IQR)

206.5 (129–271)

203 (101–303)

206.5 (133.3–262.5)

0.645

Bilirubin μmol/L median (IQR)

10 (4–16)

10 (4–20)

10 (4–15.5)

0.624

FIB4 median (IQR)

2.00 (0.94–3.61)

2.04 (1.05–7.6)

1.96 (0.88–3.38)

0.302

APRI median (IQR)

0.64 (0.3–2.08)

0.64 (0.28–2.71)

0.63 (0.3–1.9)

0.552

AST:ALT ratio median (IQR)

1.3 (0.87–1.71)

1.5 (1.0–2.16)

1.26 (0.8–1.6)

0.074

HA median (IQR)

72.1 (35.1–144.5)

PIIINP median (IQR)

8.18 (5.77–12.94)

TIMP1 median (IQR)

265.7 (198.6–364)

ELF median (IQR)

9.62 (8.93–10.6)

ELF range (lowest to highest)

(6.87–13.78)